NASDAQ:INBX Inhibrx Biosciences Q4 2025 Earnings Report $81.55 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$82.24 +0.70 (+0.85%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Inhibrx Biosciences EPS ResultsActual EPS-$2.11Consensus EPS -$2.08Beat/MissMissed by -$0.03One Year Ago EPSN/AInhibrx Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInhibrx Biosciences Announcement DetailsQuarterQ4 2025Date3/19/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsInhibrx Biosciences' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Inhibrx Biosciences Earnings HeadlinesInhibrx Biosciences: The Whole Story Rides On INBRX-106July 25 at 9:36 AM | seekingalpha.comInhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 MillionJuly 16, 2026 | prnewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.July 27 at 1:00 AM | Banyan Hill Publishing (Ad)Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaJune 15, 2026 | prnewswire.comLifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)May 18, 2026 | theglobeandmail.comInhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial ResultsMay 16, 2026 | finanznachrichten.deSee More Inhibrx Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx Biosciences and other key companies, straight to your email. Email Address About Inhibrx BiosciencesInhibrx, Inc., headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need. The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration. INBRX-109 is being evaluated in early-stage clinical studies for indications such as chronic wounds and tissue damage. In addition to its ROR2 program, Inhibrx is advancing a pipeline of preclinical assets targeting pathways including Tie2 and neuropilin-2 (NRP2), each selected for their potential to modulate angiogenesis, immune responses or fibrotic processes. Founded in 2006, Inhibrx completed its initial public offering in 2016 and trades on the Nasdaq under the ticker INBX. The company collaborates with academic research centers and strategic industry partners to accelerate the translation of its engineered proteins from discovery through clinical development. Inhibrx’s leadership team brings together expertise in molecular biology, protein engineering, translational science and regulatory affairs to drive the advancement of its therapeutic candidates toward potential regulatory approval.View Inhibrx Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks HealthierAMD and Cerbras Create A New Blueprint For HardwareThis Tiny AI Supplier Could Be More Important Than the ChipmakersIntel Earnings Reveal Whether the Chip Selloff Created a BuyRTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?Meta Earnings Put AI Spending and Ad Growth Back in Focus Upcoming Earnings PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026)Rio Tinto (7/28/2026)Sherwin-Williams (7/28/2026)Visa (7/28/2026)Waste Management (7/28/2026)Corning (7/28/2026)KLA (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
